Pharmaceutics

This page contains key pharmaceutical news on drug recalls, FDA clearance, safety communications and research. In cardiology, key pharmaceutic agents include antiplatelet therapies, anticoagulants, hypertension drugs, and drugs for heart failure and arrhythmias.   

RSS icon

PHOTO GALLERY: The trends and technologies at ASE 2023

Browse through some of the many highlights from the American Society of Echocardiography's 2023 annual meeting. 

Donislecel Lantidra FDA type 1 diabetes severe hypoglycemia

FDA approves first cellular therapy to treat type 1 diabetes

The new therapy, made from the pancreatic cells of deceased donors, is designed to help adult type 1 diabetes with severe hypoglycemia go a year or longer without needing to take insulin. 

Colchicine Lodoco Agepha Pharma price cost

What will Lodoco cost? Looking ahead after FDA’s historic approval of colchicine for CVD

“Our pricing strategy for Lodoco is focused on helping to ensure access to as many people as possible,” an executive with Agepha Pharma told Cardiovascular Business. 

The U.S. Food and Drug Administration (FDA) priority review, the FDA has cleared the Agepha Pharma USA LLC's drug Lodoco (colchicine) as the first anti-inflammatory atheroprotective cardiovascular treatment.

Cardiologists applaud FDA’s approval of colchicine for CVD

"The FDA's approval of colchicine confirms that we are entering a new era of patient care," said one veteran cardiologist familiar with the drug. 

The U.S. Food and Drug Administration (FDA) priority review, the FDA has cleared the Agepha Pharma USA LLC's drug Lodoco (colchicine) as the first anti-inflammatory atheroprotective cardiovascular treatment.

FDA approves colchicine, the first anti-inflammatory drug for treating cardiovascular disease

The FDA's approval of colchicine, which is marketed and sold under the name Lodoco, is expected to have a big impact on cardiac care and outcomes.

Thumbnail

Cardiologist kills himself after starting antibiotic, prompting coroner to share concerns

The coroner is concerned that the medication's rare side effects do not receive enough attention when it is prescribed to patients. 

healthcare value value-based care money dollar

Bitterroot Bio, a new biotech company launched by physicians and industry veterans, raises $145M

The new company formed in 2021, but waited until now to publicly launch. Its founders included two Stanford University physicians.

Antithrombotic therapy after TAVR: Comparing warfarin to DAPT, SAPT

A new retrospective study from the Mayo Clinic focused on patients with no other need for anticoagulation.

Displaying 169 - 176 of 326
Design by Adaptive Theme